Vesalius Research Center, VIB, KU Leuven, Leuven, Belgium.
Hum Mutat. 2012 Jul;33(7):1123-32. doi: 10.1002/humu.22089. Epub 2012 Apr 30.
A recent two-stage genome-wide association study (GWAS) identified five novel breast cancer susceptibility loci on chromosomes 9, 10, and 11. To provide more reliable estimates of the relative risk associated with these loci and investigate possible heterogeneity by subtype of breast cancer, we genotyped the variants rs2380205, rs1011970, rs704010, rs614367, and rs10995190 in 39 studies from the Breast Cancer Association Consortium (BCAC), involving 49,608 cases and 48,772 controls of predominantly European ancestry. Four of the variants showed clear evidence of association (P ≤ 3 × 10(-9) ) and weak evidence was observed for rs2380205 (P = 0.06). The strongest evidence was obtained for rs614367, located on 11q13 (per-allele odds ratio 1.21, P = 4 × 10(-39) ). The association for rs614367 was specific to estrogen receptor (ER)-positive disease and strongest for ER plus progesterone receptor (PR)-positive breast cancer, whereas the associations for the other three loci did not differ by tumor subtype.
最近的两阶段全基因组关联研究(GWAS)在染色体 9、10 和 11 上确定了五个新的乳腺癌易感性位点。为了更可靠地估计与这些位点相关的相对风险,并通过乳腺癌亚型研究可能的异质性,我们对来自乳腺癌协会联盟(BCAC)的 39 项研究中的变体 rs2380205、rs1011970、rs704010、rs614367 和 rs10995190 进行了基因分型,这些研究共涉及 49608 例病例和 48772 例对照,主要为欧洲血统。其中四个变体显示出明显的关联证据(P ≤ 3×10(-9) ),而 rs2380205 则显示出微弱的关联证据(P = 0.06)。最强的证据是位于 11q13 的 rs614367(每个等位基因的优势比为 1.21,P = 4×10(-39) )。rs614367 的关联仅针对雌激素受体(ER)阳性疾病,并且在 ER 加孕激素受体(PR)阳性乳腺癌中最强,而其他三个位点的关联与肿瘤亚型无关。